Pyronaridine for treatment of Plasmodium ovale and Plasmodium malariae infections.
The clinical efficacy of oral pyronaridine was assessed in 22 symptomatic Cameroonian patients infected with Plasmodium ovale or Plasmodium malariae. All patients were cured on or before day 4. In vitro drug assays confirmed the sensitivity of P. ovale and P. malariae isolates to chloroquine and pyronaridine.
Ringwald
P
P
Institut Français de Recherche Scientifique pour le Développement en Coopération (ORSTOM), Organisation de Coordination pour la lutte contre les Endémies en Afrique Centrale, Yaoundé, Cameroon.
Bickii
J
J
Same-Ekobo
A
A
Basco
L K
LK
D000293:Adolescent; D000328:Adult; D000818:Animals; D000962:Antimalarials / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006801:Humans; D008288:Malaria / Q000188:drug therapy* / Q000469:parasitology; D008297:Male; D009287:Naphthyridines / Q000008:administration & dosage / Q000627:therapeutic use*; D010961:Plasmodium; D010965:Plasmodium malariae; D013608:Tablets, Enteric-Coated
D000962:Antimalarials; D009287:Naphthyridines; D013608:Tablets, Enteric-Coated; C027871:pyronaridine